wegovy

Congressman Bernie Sanders (I-Vt.) has been known to tussle with public companies over their high prices or anticompetitive behavior, including pharmaceutical companies and their high costs. In his newest battle, Sanders is taking on the growing popularity of weight-loss drugs and diabetes...

What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administered for diabetes and obesity treatment. As reported by CNBC, investors initially expressed concerns about these drugs’ market impact. However, with...

How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid vaccine to market during the pandemic, and now tackling the obesity epidemic. Those with obesity drugs already on the market...

Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and conditions associated with obesity and diabetes, including Novo Nordisk, maker of the blockbuster diet drug Ozempic. The Tema Cardiovascular and Metabolics...

The FDA has approved Eli Lilly And Co's (NYSE: LLY) Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.  The active...

GLP-1s, or weight-loss drugs like Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy, are helping millions of Americans manage their weight and diabetes. But what if you could get some of the benefits of Ozempic and Wegovy just by altering your diet? Semaglutide, the primary ingredient in...

Ozempic, Novo Nordisk’s (NYSE: NVO) diabetes drug, is now popular for weight loss. The rise of the drug could become a major headwind for other companies that provide weight-loss services such as liposuction and bariatric surgeries. Some companies are already seeing the impact of...

Prescription weight loss drugs Ozempic, Wegovy and Mounjaro have dominated headlines in 2023 with increased interest and the impact being discussed by food and drink companies. Here's a look at the consumer segments that might be driving the enthusiasm and demand for these GLP-1 drugs. What...

Following a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic, Danish pharmaceutical company Novo Nordisk (NYSE:NVO) has revised its full-year sales and operating profit outlook. Novo Nordisk is now forecasting a sales growth for 2023 in local currencies of 32% to 38...

Eli Lilly & Co. (NYSE:LLY) has been a high-flier among the mega-cap pharma stocks this year, as the company leverages the obesity drug craze. Prominent Tesla investor and Future Fund Manager Gary Black weighed in on the stock’s run-up and its future trajectory. What Happened: Lilly stock...

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday. The Dow traded up 0.4% to 33,739.30 while the NASDAQ rose 0.58% to 13,562.84. The S&P 500 also rose, gaining 0.52% to 4,358.24. These are the top stocks that gained the attention of...

Coverage for obesity medications, including Novo Nordisk A/S's (NYSE: NVO) Wegovy, is expected to expand among U.S. employers, according to a new survey conducted by healthcare program provider Accolade Inc (NASDAQ: ACCD) and research firm Savanta. The survey indicates...

PepsiCo (NASDAQ: PEP) is among the food and beverage stocks that could see declining sales and momentum lost from investors due to new weight loss drugs. Here’s a look at where the soft drink and snack giant stands ahead of its third-quarter (Q3) financial results. Earnings Estimates: Pepsi...

Stocks in the food and beverage industry experienced their most challenging week since May 2022, further extending the declines seen in the preceding weeks. The First Trust Nasdaq Food & Beverage ETF (NYSE:FTXG) plummeted by over 5% this week, marking its third consecutive week of losses and...

Shares of WW International Inc (NASDAQ:WW) spiked as much as 15% on Friday after Blue Cross Blue Shield of Michigan and Blue Care Network announced changes to the prior authorization coverage criteria for certain brand-name weight loss medications. What Happened: Starting Oct. 1, Blue Cross Blue...